Dr. Maller is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Connect with other colleagues in the same hospital or clinic
- Search all U.S. specialist profiles and refer a patient
- Read the latest clinical news and earn CME/CEU credits
Office
1310 Road
Wynnewood
Wynnewood, PA 19096Phone+1 610-246-3571- Is this information wrong?
Education & Training
- Children's Hospital of PhiladelphiaFellowship, Pediatric Gastroenterology, 1984 - 1987
- Children's Hospital/Boston Medical CenterFellowship, Adolescent Medicine, 1983 - 1984
- Children's Hospital/Boston Medical CenterResidency, Pediatrics, 1980 - 1983
- Harvard Medical SchoolClass of 1980
Certifications & Licensure
- PA State Medical License 1984 - 2024
- American Board of Pediatrics Pediatrics
- American Board of Pediatrics Pediatric Gastroenterology
Publications & Presentations
PubMed
- 12 citationsExtraintestinal manifestations at baseline, and the effect of tofacitinib, in patients with moderate to severe ulcerative colitis.David T. Rubin, Walter Reinisch, Thomas Greuter, Paulo Gustavo Kotze, Marcia Pinheiro, Rajiv Mundayat, E Maller, Marc Fellmann, Nervin Lawendy, Irene Modesto, Stephan ...> ;Therapeutic Advances in Gastroenterology. 2021 May 16
- 6 citationsThe Impact of Raising the Bar for Clinical Trials in Ulcerative Colitis.Bruce E. Sands, Adam S. Cheifetz, Chudy I. Nduaka, Daniel Quirk, Wenjin Wang, E Maller, Gary S. Friedman, Chinyu Su, Peter D.R. Higgins> ;Journal of Crohn's & Colitis. 2019 Sep 19
- 24 citationsLong-term safety and tolerability of oral tofacitinib in patients with Crohn’s disease: results from a phase 2, open-label, 48-week extension studyJulián Panés, Geert R. D'Haens, Peter D.R. Higgins, Linda Mele, Michele Moscariello, Gary Chan, Wenjin Wang, Wojciech Niezychowski, Chinyu Su, Eric S. Maller> ;Alimentary Pharmacology & Therapeutics. 2019 Feb 1
- Join now to see all
Press Mentions
- Consensus: Guidelines: Best Practices for Detection, Assessment and Management of Suspected Acute Drug-Induced Liver Injury During Clinical Trials in Patients with Nonalcoholic SteatohepatitisFebruary 13th, 2020
Grant Support
- Lamivudine In Pediatric Subjects With Hepatitis BNational Center For Research Resources2000–2002
- Intron A PLUS Ribavirin In Pediatric Hepatitis CNational Center For Research Resources2000–2002
- Ursodeoxychloric Acid In Cystic Fibrosis Associated Liver DiseaseNational Center For Research Resources1995–1997
- Dose Response Ursodeoxycholic Acid In Cystic Fibrosis-Associated Liver DiseaseNational Center For Research Resources1994–1995
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: